![Konstantinos Efthymiopoulos](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Konstantinos Efthymiopoulos
Président chez SynAffix BV
Postes actifs de Konstantinos Efthymiopoulos
Sociétés | Poste | Début | Fin |
---|---|---|---|
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Président | 07/01/2016 | - |
Independent Dir/Board Member | 07/01/2016 | - |
Historique de carrière de Konstantinos Efthymiopoulos
Anciens postes connus de Konstantinos Efthymiopoulos
Sociétés | Poste | Début | Fin |
---|---|---|---|
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Fondateur | 18/06/2010 | - |
Farmitalia Carlo Erba SRL | Corporate Officer/Principal | - | - |
Glaxo, Inc. | Corporate Officer/Principal | - | - |
Glaxo Wellcome, Inc. | Corporate Officer/Principal | - | - |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Directeur Technique/Scientifique/R&D | - | - |
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | President | - | - |
Formation de Konstantinos Efthymiopoulos
University of Strasbourg | Doctorate Degree |
National & Kapodistrian University of Athens | Graduate Degree |
University of London | Masters Business Admin |
Statistiques
Internationale
Royaume-Uni | 4 |
Etats-Unis | 3 |
France | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Graduate Degree | 2 |
President | 1 |
Sectorielle
Health Technology | 7 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 7 |
---|---|
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Health Technology |
Glaxo Wellcome, Inc. | Health Technology |
Glaxo, Inc. | |
Farmitalia Carlo Erba SRL | Health Technology |
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |